FDA approves new treatment for certain breast cancers

Shares of US pharma major Eli Lilly (NYSE: LLY) were barely moved yesterday even though the company received approval from the US Food and Drug Administration for Verzenio (abemaciclib), under the agency’s Breakthrough and Priority Review designation programs.

The FDA approval is for the treatment of adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy).

“The FDA approval of this new treatment is an important milestone for people with advanced breast cancer as there is a pressing need for new medicines that address the significant treatment challenges these patients face,” said Dr Levi Garraway, senior vice president, product development and medical affairs for Lilly Oncology, adding:, “Today’s announcement further underscores Lilly’s commitment to help people with cancer live longer, healthier, more active lives.”